In addition, patients genetically shown to have the EGFR CA repeats SS genotype and a tumor with EGFR protein overexpression had a worst prognosis in terms of DFS (p = 0.002; HR = 4.11; 95% CI, 1.66–10.14) compared to those patients with the EGFR CA repeat LL/LS genotype and/or no EGFR protein overexpression and that this significant relationship still existed (p = 0.04; HR = 2.68; 95% CI, 1.03–6.98) after multivariate adjustment for age, primary tumor status, lymph node metastasis, tumor depth, and tumor cell differentiation. The gene discussed is EGFR; the disease is metastatic malignant neoplasm in the lymph nodes.